Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Curious about Monday at ASH, nothing noted about this

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Dec 12, 2021 6:37pm

162 Views

Post# 34223588

RE:RE:Curious about Monday at ASH, nothing noted about this

Reolysin was the trade name in use for about fifiteen years.

The reason given by ONC for the change to Pelareorep has always stuck me as being completely fabricated and pure bogus nonsense.

I believe the name was changed from Reolysin to Pelareorep for strategic purposes... to help bury fifteen years worth of failed clinical trials and "re-brand" the virus as they move ever so slowly toward BC phase three.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages